35480-46-7

Usage

Classification

Nonsteroidal anti-inflammatory drug (NSAID)

Function

Reduces pain and inflammation in conditions such as arthritis by inhibiting the production of certain chemicals in the body that cause pain and inflammation

Additional Use

Treatment of acute myocardial infarction and transient ischemic attacks, as it can help prevent blood clots from forming and reduce the risk of further cardiovascular events

Administration

Orally in the form of tablets or capsules

Side Effects

May include gastrointestinal discomfort, bleeding, and allergic reactions

Importance

An effective and valuable medication for managing pain and inflammation associated with various medical conditions.

Upstream product

• 119-36-8 methyl salicylate 
• 27831-94-3 N-((4-nitrophenyl)sulfonyl)benzamide 
• 75-89-8 2,2,2-trifluoroethanol 
• 118-91-2 ortho-chlorobenzoic acid 
• 35453-44-2 1-methyl 2-(2,2,2-trifluoroethoxy)benzoate 

Downstream Products

• 35480-31-0 methyl 2,5-bis(2,2,2-trifluoroethoxy)benzoate 
• 847786-18-9 5-bromo-2-(2,2,2-trifluoroethoxy)benzoic acid 

Relevant academic research and scientific papers

Palladium-Catalyzed C-H Trifluoroethoxylation of N-Sulfonylbenzamides

The trifluoroethyl aryl ethers are important motifs in drug molecules. However, a report devoted specifically to the study of transition-metal-catalyzed C-H trifluoroethoxylation has not been reported to date. A protocol of Pd(II)-catalyzed o-C-H trifluor

PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof

Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof that involves the use of the 2-halobenzoic acid and its derivatives as a starting material. The use of this process also allows for the synthesis of a novel intermediate useful in the production of Flecainide. This new process is an inexpensive and efficient process for the manufacture of these compounds.

Polyfluoroalkoxy-substituted aromatic carboxylic amides and hydrozides

Acyl halides, esters, amides, hydrazides and salts as well as the acid form derived from aromatic acids substituted by polyfluoroalkoxy groups. These compounds are valuable as synthetic intermediates in the preparation of physiologically active compounds.